



BALKAN MYELOMA STUDY GROUP

ASSEMBLY MEETING

18rd November, Bucharest, Romania

PROGRAM

17.11.2023.

15.00-20.00 Arrival and registration of BMSG Assembly's members and participating delegates

20.30-22.00 BMSG's Assembly Dinner

18.11.2023.

09.00-09.10 Words of Welcome

Prof dr Daniel Coriu, Dr Sorina Badelita on behalf of the hosting Romanian Hematology Association

09.10 - 09.30 OVERVIEW OF THE BMSG's ACTIVITIES, DEVELOPMENT AND PERSPECTIVES

Prof dr Meletios Athanasios Dimopoulos, BMSG President

Prof dr Meral Beksac, BMSG Vice President

09.30 – 10.45 BMSG's ROUND TABLE: Incorporation of new molecular methodology in current clinical practice; accessibility to the new drugs; participation in international projects, registries and clinical trials – regional experiences

Moderators: Prof dr Meletios A. Dimopoulos; Prof dr Daniel Coriu

Participants: Members of BMSG Assembly representing BMSG's participating countries –

BMSG survey's* 10min presentations:

Greece, Bulgaria, Albania, Slovenia, Croatia, Romania

Discussion

10.45-11.15 Coffee break

11.15 – 12.30 BMSG's ROUND TABLE: Incorporation of new molecular methodology in current clinical practice; accessibility to the new drugs; participation in international projects, registries and clinical trials – regional experiences

Moderators: Prof dr Meral Beksac; Prof dr Jelena Bila

Participants: Members of BMSG Assembly representing BMSG's participating countries – BMSG survey's* 10min presentations:

Turkey, North Macedonia, Montenegro, Bosnia and Herzegovina, Serbia

Discussion

12.30-13.45 BMSG REGISTRY: CURRENT STATUS AND FUTURE ACTIVITIES

Prof dr Efstathios Kastitis, BMSG's Registry Leader

BMSG Registry's administrators of INAB/CERTH

- Current BMSG registry status – discussion on participation
- BMSG registry derived abstracts and papers
- Challenges in the maintenance of the registry - presentation of key missing data
- Discussion on the design and variables of the registry (updates, upgrades etc)
- Future projects based on BMSG registry
- Possibilities for collaborative interaction with other databases and registries

Discussion

13.45-14.00 CONCLUDING REMARKS

Prof dr Meletios Athanasios Dimopoulos, BMSG President

14.00-16.00 Lunch

17.00-18.00 – Romanian Athenaeum – Visit and Quartet Recital

19.30 – Dinner at “La Dome Restaurant”

19.11.2023. Departure

** **NOTE:** Presentations should be based on the following survey regarding access to treatment and the possibility of Fish studies in the attending countries*



BALKAN MYELOMA STUDY GROUP

ASSEMBLY MEETING

18rd November, Bucharest, Romania

SURVEY's QUESTIONS

- **Access to Daratumumab in the first line of treatment (transplant eligible/ineligible)**
- **Approved therapies for Lenalidomide refractory patients**
- **Approved therapies for Daratumumab and Lenalidomide refractory patients**
- **Access to bispecific therapies**
- **Access to Denosumab therapy (for: all MM patients; solid tumors only; patients may have access after documentation for renal impairment)**
- **Fish studies with isolated CD138 plasma cells for del17p, t (11;14), t(4;14), t(14;16), 1q gain (number of Centers per country: less than 5 centers; 6-10 centers; all centers)**